Cytokinetics licenses aficamten Japan rights to Bayer for €50M upfront, up to €580M milestones

CYTOKINETICS INC

Upfront payment of €50 million from Bayer; additional clinical/commercial launch milestones up to €90 million.
Commercial milestone payments up to €490 million based on net sales thresholds.
Tiered royalties on Japan net sales ranging from high-teens to low-thirty percent.
Bayer responsible for development and commercialization at its own cost; Cytokinetics retains rights to ACACIA-HCM and CEDAR-HCM trials in Japan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.